Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment

This publication has 19 references indexed in Scilit:

• Cost Effectiveness of Intraperitoneal Compared With Intravenous Chemotherapy for Women With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
  Journal of Clinical Oncology, 2008
• Serum protein markers for early detection of ovarian cancer
  Proceedings of the National Academy of Sciences, 2005
• Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer
  Supportive Care in Cancer, 2004
• A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians
  Gynecologic Oncology, 2004
• Treatment Preferences in Recurrent Ovarian Cancer
  Gynecologic Oncology, 2002
• The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations.
  1999
• A review of the use of health status measures in economic evaluation.
  Health Technology Assessment, 1999
• Perceptions of Cisplatin-Related Toxicity among Ovarian Cancer Patients and Gynecologic Oncologists
  Gynecologic Oncology, 1998
• Palliative therapy in advanced ovarian cancer
  Anti-Cancer Drugs, 1998
• Cost–Utility Analysis of Paclitaxel in Combination with Cisplatin for Patients with Advanced Ovarian Cancer
  Gynecologic Oncology, 1997